Biomarkers in sepsis

Mervyn Singer, Mervyn Singer

Abstract

Purpose of review: This review discusses the current developments in biomarkers for sepsis.

Recent findings: With quantum leaps in technology, an array of biomarkers will become available within the next decade as point-of-care tools that will likely revolutionize the management of sepsis. These markers will facilitate early and accurate diagnosis, faster recognition of impending organ dysfunction, optimal selection and titration of appropriate therapies, and more reliable prognostication of risk and outcome. These diagnostics will also enable an improved characterization of the biological phenotype underlying sepsis and thus a better appreciation of the condition.

Summary: The potential for novel biomarkers in sepsis will need to be properly realized with considerable funding, academic-industry collaborations, appropriate investigations and validation in heterogenous populations, but these developments do hold the capacity to transform patient care and outcomes.

Figures

Box 1
Box 1
no caption available

References

    1. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055–2064.

    2. This trial resulted in the withdrawal of the only licensed drug for sepsis immunomodulation.

    1. Nature Medicine News Biologic drugs set to top 2012 sales. Nat Med 2012; 18:636.
    1. Angus DC. The search for effective therapy for sepsis: back to the drawing board? JAMA 2011; 306:2614–2615.
    1. Venet F, Davin F, Guignant C, et al. Early assessment of leukocyte alterations at diagnosis of septic shock. Shock 2010; 34:358–363.
    1. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180:640–648.
    1. Döcke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3:678–681.
    1. Circiumaru B, Baldock G, Cohen J. A prospective study of fever in the intensive care unit. Intensive Care Med 1999; 25:668–673.
    1. Tang BM, Eslick GD, Craig JC, et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and metaanalysis. Lancet Infect Dis 2007; 7:210–217.
    1. Wu Y, Wang F, Fan X, et al. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. Crit Care 2012; 16:R229.
    1. Kofoed K, Andersen O, Kronborg G, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007; 11:R38.
    1. Gibot S, Béné MC, Noel R, et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012; 186:65–71.

    2. A demonstration that a combination biomarker panel is superior as a diagnostic compared with the individual biomarkers.

    1. Lukaszewski RA, Yates AM, Jackson MC, et al. Presymptomatic prediction of sepsis in intensive care unit patients. Clin Vaccine Immunol 2008; 15:1089–1094.
    1. Sutherland A, Thomas M, Brandon RA, et al. Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis. Crit Care 2011; 15:R149.

    2. A transcriptomic approach to diagnose sepsis and differentiate it from other inflammatory conditions, for example, surgery.

    1. Maslove DM, Tang BM, McLean AS. Identification of sepsis subtypes in critically ill adults using gene expression profiling. Crit Care 2012; 16:R183.
    1. Trof RJ, Di Maggio F, Leemreis J, Groeneveld ABJ. Biomarkers of acute renal injury and renal failure. Shock 2006; 26:245–253.
    1. Srisawat N, Wen X, Lee M, et al. Urinary biomarkers and renal recovery in critically ill patients with renal support. Clin J Am Soc Nephrol 2011; 6:1815–1823.

    2. A demonstration that urine biomarkers can predict the recovery of renal function.

    1. Moreno R, Vincent JL, Matos R, et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Intensive Care Med 1999; 25:686–696.
    1. Recknagel P, Gonnert FA, Westermann M, et al. Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med 2012; 9:e1001338.
    1. Marshall JC, Reinhart K. International Sepsis Forum. Biomarkers of sepsis. Crit Care Med 2009; 37:2290–2298.
    1. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862–871.
    1. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111–124.
    1. Briegel J, Sprung CL, Annane D, et al. Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. Intensive Care Med 2009; 35:2151–2156.
    1. Osuchowski MF, Connett J, Welch K, et al. Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. Crit Care Med 2009; 37:1567–1573.
    1. Hicks CW, Sweeney DA, Danner RL, et al. Beneficial effects of stress-dose corticosteroid therapy in canines depend on the severity of staphylococcal pneumonia. Intensive Care Med 2012; 38:2063–2071.
    1. Shorr AF, Bernard GR, Dhainaut J-F, et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care 2006; 10:R92.
    1. Shorr AF, Janes JM, Artigas A, et al. Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). Crit Care 2010; 14:R229.
    1. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 2011; 53:379–387.
    1. Layios N, Lambermont B, Canivet J-L, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 2012; 40:2304–2309.
    1. Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011; 39:2048–2058.
    1. Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167:1655–1663.
    1. Shapiro NI, Trzeciak S, Hollander JE, et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 2009; 37:96–104.
    1. Parker SM, Shelhamer JH, Natanson C, et al. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 1987; 15:923–929.
    1. Wacharasint P, Nakada T-A, Boyd JH, et al. Normal-range blood lactate concentration in septic shock is prognostic and predictive. Shock 2012; 38:4–10.
    1. Mtove G, Nadjm B, Hendriksen IC, et al. Point-of-care measurement of blood lactate in children admitted with febrile illness to an African district hospital. Clin Infect Dis 2011; 53:548–554.
    1. Schmidt H, Hoyer D, Hennen R, et al. Autonomic dysfunction predicts both 1- and 2-month mortality in middle-aged patients with multiple organ dysfunction syndrome. Crit Care Med 2008; 36:967–970.
    1. Brenner T, Hofer S, Rosenhagen C, et al. Macrophage migration inhibitory factor (MIF) and manganese superoxide dismutase (MnSOD) as early predictors for survival in patients with severe sepsis or septic shock. J Surg Res 2010; 164:e163–e171.
    1. Arnalich F, López J, Codoceo R, et al. Relationship of plasma leptin to plasma cytokines and human survival in sepsis and septic shock. J Infect Dis 1999; 180:908–911.
    1. McClintock D, Zhuo H, Wickersham N, et al. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care 2008; 12:R41.
    1. Martin K, Borgel D, Lerolle N, et al. Decreased ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007; 35:2375–2382.
    1. Que Y-A, Delodder F, Guessous I, et al. Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management. Crit Care 2012; 16:R114.
    1. Ricciuto DR, Santos dos CC, Hawkes M, et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 2011; 39:702–710.
    1. Hayes MA, Timmins AC, Yau EH, et al. Oxygen transport patterns in patients with sepsis syndrome or septic shock: influence of treatment and relationship to outcome. Crit Care Med 1997; 25:926–936.
    1. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360:219–223.
    1. Carré JE, Orban J-C, Re L, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med 2010; 182:745–751.
    1. Annane D, Sébille V, Troché G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283:1038–1045.
    1. Wang F, Pan W, Wang H, et al. Relationship between thyroid function and ICU mortality: a prospective observation study. Crit Care 2012; 16:R11.
    1. Landesberg G, Gilon D, Meroz Y, et al. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J 2012; 33:895–903.
    1. John J, Woodward DB, Wang Y, et al. Troponin-I as a prognosticator of mortality in severe sepsis patients. J Crit Care 2010; 25:270–275.
    1. Wang F, Wu Y, Tang L, et al. Brain natriuretic peptide for prediction of mortality in patients with sepsis: a systematic review and meta-analysis. Crit Care 2012; 16:R74.
    1. Nguyen DN, Spapen H, Su F, et al. Elevated serum levels of S-100beta protein and neuron-specific enolase are associated with brain injury in patients with severe sepsis and septic shock. Crit Care Med 2006; 34:1967–1974.
    1. Rhodes A, Wort SJ, Thomas H, et al. Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients. Crit Care 2006; 10:R60.
    1. Stachon A, Segbers E, Holland-Letz T, et al. Nucleated red blood cells in the blood of medical intensive care patients indicate increased mortality risk: a prospective cohort study. Crit Care 2007; 11:R62.
    1. Osuka A, Shimizu K, Ogura H, et al. Prognostic impact of fecal pH in critically ill patients. Crit Care 2012; 16:R119.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться